Robert Grubb to Middle Aged
This is a "connection" page, showing publications Robert Grubb has written about Middle Aged.
Connection Strength
0.644
-
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol. 2013 Mar; 189(3):871-7.
Score: 0.029
-
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
Score: 0.023
-
High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst. 2007 Sep 19; 99(18):1355-6.
Score: 0.021
-
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007 Jun; 177(6):2074-9; discussion 2079-80.
Score: 0.020
-
Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol. 2006 Jun; 3(6):306-7.
Score: 0.019
-
Use of titanium staples during upper tract laparoscopic reconstructive surgery: initial experience. J Urol. 2002 Oct; 168(4 Pt 1):1366-9.
Score: 0.015
-
One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urol. 2021 May 17; 21(1):81.
Score: 0.013
-
Recurrent Hemispheric Stroke Syndromes in Symptomatic Atherosclerotic Internal Carotid Artery Occlusions: The Carotid Occlusion Surgery Study Randomized Trial. Neurosurgery. 2020 07 01; 87(1):137-141.
Score: 0.013
-
Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020 04; 13(4):367-376.
Score: 0.012
-
The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. Cancer Causes Control. 2019 Aug; 30(8):871-876.
Score: 0.012
-
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Med. 2019 07; 8(8):3698-3709.
Score: 0.012
-
Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer. 2019 03 01; 125(5):798-806.
Score: 0.011
-
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
Score: 0.011
-
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol. 2018 06; 1(2):143-148.
Score: 0.011
-
Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram. Urology. 2018 03; 113:119-128.
Score: 0.011
-
Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
Score: 0.010
-
Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. J Urol. 2017 12; 198(6):1397-1403.
Score: 0.010
-
Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial. Cancer Causes Control. 2017 Aug; 28(8):889-898.
Score: 0.010
-
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials. 2017 04 18; 18(1):181.
Score: 0.010
-
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123(4):592-599.
Score: 0.010
-
Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? Urology. 2017 04; 102:190-197.
Score: 0.010
-
Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes. Neurosurgery. 2016 Jul; 79(1):23-32.
Score: 0.010
-
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104.
Score: 0.010
-
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Dec; 107(12):djv279.
Score: 0.009
-
Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation. Urol Oncol. 2015 Jul; 33(7):330.e9-17.
Score: 0.009
-
Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. BJU Int. 2016 Jan; 117(1):145-54.
Score: 0.009
-
Physical activity and benign prostatic hyperplasia-related outcomes and nocturia. Med Sci Sports Exerc. 2015 Mar; 47(3):581-92.
Score: 0.009
-
Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery. 2014 Oct; 75(4):347-54; discussion 354-5; quiz 355.
Score: 0.008
-
Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery. 2014 Oct; 75(4):356-63; discussion 363.
Score: 0.008
-
Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2374-82.
Score: 0.008
-
Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). BJU Int. 2014 Jul; 114(1):98-103.
Score: 0.008
-
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol. 2015 Jan; 33(1):69-75.
Score: 0.008
-
Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial: main results. Neurology. 2014 Mar 04; 82(9):744-51.
Score: 0.008
-
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol. 2014 Jan; 16(1):123-30.
Score: 0.008
-
The safety of aeroplane travel in patients with symptomatic carotid occlusion. J Neurol Neurosurg Psychiatry. 2014 Apr; 85(4):435-7.
Score: 0.008
-
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2241-9.
Score: 0.008
-
Biopsy of the superficial cortex: predictors of effectiveness and outcomes. Neurosurgery. 2013 Aug; 73(2):224-31; discussion 231-2; quiz 232.
Score: 0.008
-
Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010. Am J Epidemiol. 2013 Jun 15; 177(12):1368-77.
Score: 0.008
-
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer. 2013 Jun 15; 119(12):2223-9.
Score: 0.008
-
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013 Apr 01; 73(7):2211-20.
Score: 0.008
-
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urol Oncol. 2014 Jan; 32(1):34.e9-18.
Score: 0.008
-
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol. 2013 Sep; 64(3):372-8.
Score: 0.008
-
Adenocarcinoma in an ileal conduit. J Urol. 2013 Feb; 189(2):697-8.
Score: 0.007
-
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
Score: 0.007
-
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601.
Score: 0.007
-
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
Score: 0.007
-
Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006. J Urol. 2012 Jan; 187(1):32-8.
Score: 0.007
-
Intestinal adenocarcinoma arising in urinary conduits. Oncol Rep. 2012 Feb; 27(2):371-5.
Score: 0.007
-
Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urol Oncol. 2013 Aug; 31(6):894-8.
Score: 0.007
-
Positive margin during partial nephrectomy: does cancer remain in the renal remnant? Urology. 2011 Jun; 77(6):1400-3.
Score: 0.007
-
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61.
Score: 0.006
-
Splenic injury during percutaneous nephrolithotomy: a case report with novel management technique. J Endourol. 2010 Apr; 24(4):541-5.
Score: 0.006
-
Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol. 2010 Mar; 183(3):909-14.
Score: 0.006
-
Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol. 2010 Feb; 183(2):455-8.
Score: 0.006
-
Preoperative sensorimotor mapping in brain tumor patients using spontaneous fluctuations in neuronal activity imaged with functional magnetic resonance imaging: initial experience. Neurosurgery. 2009 Dec; 65(6 Suppl):226-36.
Score: 0.006
-
The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol. 2011 Nov-Dec; 29(6):738-44.
Score: 0.006
-
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):4314-20.
Score: 0.006
-
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
Score: 0.006
-
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51.
Score: 0.006
-
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
Score: 0.005
-
Combined surgical resection and stereotactic radiosurgery for treatment of cerebral metastases. Surg Neurol. 2009 Mar; 71(3):280-8, disucssion 288-9.
Score: 0.005
-
Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int. 2008 Jan; 101(2):181-5.
Score: 0.005
-
Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007 May; 99(5):1041-6.
Score: 0.005
-
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007 Apr 15; 109(8):1689-95.
Score: 0.005
-
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
Score: 0.005
-
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006 Aug; 68(2):352-6.
Score: 0.005
-
Results of compliance with prostate cancer screening guidelines. J Urol. 2005 Aug; 174(2):668-72; discussion 672.
Score: 0.004
-
Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage. J Neurosurg. 2005 Jul; 103(1):25-30.
Score: 0.004
-
Evaluation and management of renal tumors in the Birt-Hogg-Dub? syndrome. J Urol. 2005 May; 173(5):1482-6.
Score: 0.004
-
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
Score: 0.004
-
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8.
Score: 0.004
-
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004 Jul; 172(1):63-5.
Score: 0.004
-
Laparoscopic pyeloplasty for secondary ureteropelvic junction obstruction. J Urol. 2003 Jun; 169(6):2037-40.
Score: 0.004